NRx Pharma 2023 net loss $30.2M; expects top-line data this month for NRX-101 TRBD trial

NRX Pharmaceuticals, Inc.

2024-Q1 EPS reported -$0.74

Net loss for full-year 2023: $30.2M vs $39.8M in 2022; Q4 2023 loss $4.3M vs $10.2M in Q4 2022.
Cash $4.6M at Dec 31, 2023; added $8M in Q1 2024 via equity sales and $5.1M milestone from Alvogen/Lotus.
Expects top-line data in April 2024 from Phase 2b/3 trial of NRX-101 in TRBD; achieved 94% rater concordance.
Plans to spin out HOPE Therapeutics for IV Ketamine; NDA filing expected by June 2024; term sheets for $60M investment.
Reduced G&A expenses 50% YoY to $14.2M in 2023 from $27.3M; corporate overhead decreased by half.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

NRX Pharmaceuticals, Inc. reported financial results for the fourth fiscal quarter and year ending December 31, 2023.

Period: the fourth fiscal quarter and year ending December 31, 2023
Result: reported results

Exact text from the filing

On April 1, 2024, NRx Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth fiscal quarter and year ending December 31, 2023 and provided a business update.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-24-004570

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.